AARD — Aardvark Therapeutics Balance Sheet
0.000.00%
Annual balance sheet for Aardvark Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 16.1 | 9.99 | 73.7 | 110 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 16.5 | 10.4 | 74.1 | 112 |
| Net Property, Plant And Equipment | 0.252 | 0.155 | 0.735 | 0.355 |
| Other Long Term Assets | ||||
| Total Assets | 16.8 | 10.5 | 77.5 | 117 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 0.595 | 1.38 | 4.93 | 10.5 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 0.776 | 1.43 | 5.39 | 10.5 |
| Redeemable Preferred Stock | ||||
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 16 | 9.1 | 72.1 | 107 |
| Total Liabilities & Shareholders' Equity | 16.8 | 10.5 | 77.5 | 117 |
| Total Common Shares Outstanding | ||||
| Total Preferred Shares Outstanding |